In conclusion, our data show that investigational PI3K inhibitors can block the growth of Ph+ B-ALL cell lines but are likely to be most effective when used in combination with Bcr-Abl inhibitors and provide an important preclinical rationale for future clinical applications. Here, PIK3CD is linked to acute lymphoblastic leukemia.